A detailed history of J. L. Bainbridge & Co., Inc. transactions in Biogen Inc. stock. As of the latest transaction made, J. L. Bainbridge & Co., Inc. holds 121,142 shares of BIIB stock, worth $18.1 Million. This represents 2.29% of its overall portfolio holdings.

Number of Shares
121,142
Previous 60,604 99.89%
Holding current value
$18.1 Million
Previous $14 Million 67.14%
% of portfolio
2.29%
Previous 1.4%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$189.07 - $236.8 $11.4 Million - $14.3 Million
60,538 Added 99.89%
121,142 $23.5 Million
Q2 2024

Aug 13, 2024

BUY
$190.52 - $236.72 $2.02 Million - $2.51 Million
10,586 Added 21.16%
60,604 $14 Million
Q1 2024

May 09, 2024

BUY
$212.02 - $267.71 $10.6 Million - $13.4 Million
50,018 New
50,018 $10.8 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track J. L. Bainbridge & Co., Inc. Portfolio

Follow J. L. Bainbridge & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of J. L. Bainbridge & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on J. L. Bainbridge & Co., Inc. with notifications on news.